141 related articles for article (PubMed ID: 16466892)
1. Susceptibility studies of piperazinyl-cross-linked fluoroquinolone dimers against test strains of Gram-positive and Gram-negative bacteria.
Kerns RJ; Rybak MJ; Cheung CM
Diagn Microbiol Infect Dis; 2006 Apr; 54(4):305-10. PubMed ID: 16466892
[TBL] [Abstract][Full Text] [Related]
2. Pyrrolobenzodiazepine dimers: novel sequence-selective, DNA-interactive, cross-linking agents with activity against Gram-positive bacteria.
Hadjivassileva T; Thurston DE; Taylor PW
J Antimicrob Chemother; 2005 Sep; 56(3):513-8. PubMed ID: 16024592
[TBL] [Abstract][Full Text] [Related]
3. Antimicrobial susceptibility of tigecycline and comparators against bacterial isolates collected as part of the TEST study in Europe (2004-2007).
Nørskov-Lauritsen N; Marchandin H; Dowzicky MJ
Int J Antimicrob Agents; 2009 Aug; 34(2):121-30. PubMed ID: 19342205
[TBL] [Abstract][Full Text] [Related]
4. [In vitro fluoroquinolone resistance in ocular bacterial isolates].
Sun XG; Wang ZQ; Li R; Chen L; Jin XY; Luo SY
Zhonghua Yan Ke Za Zhi; 2003 Mar; 39(3):163-6. PubMed ID: 12880574
[TBL] [Abstract][Full Text] [Related]
5. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
Jones RN; Sader HS; Fritsche TR; Pottumarthy S
Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923
[TBL] [Abstract][Full Text] [Related]
6. [Comparative bacteriologic activity of norfloxacin, ofloxacin and pefloxacin against 320 Gram-negative bacilli resistant and non-resistant to nalidixic acid and cephalosporins].
Croize J; Le Noc P; Bryskier A; Robert J
Pathol Biol (Paris); 1985 Jun; 33(5 Pt 2):564-8. PubMed ID: 3937128
[TBL] [Abstract][Full Text] [Related]
7. Antimicrobial activity of a novel peptide deformylase inhibitor, LBM415, tested against respiratory tract and cutaneous infection pathogens: a global surveillance report (2003-2004).
Watters AA; Jones RN; Leeds JA; Denys G; Sader HS; Fritsche TR
J Antimicrob Chemother; 2006 May; 57(5):914-23. PubMed ID: 16549511
[TBL] [Abstract][Full Text] [Related]
8. Bactericidal activity and target preference of a piperazinyl-cross-linked ciprofloxacin dimer with Staphylococcus aureus and Escherichia coli.
Zhao X; Quinn B; Kerns R; Drlica K
J Antimicrob Chemother; 2006 Dec; 58(6):1283-6. PubMed ID: 17003060
[TBL] [Abstract][Full Text] [Related]
9. Potency and spectrum of garenoxacin tested against an international collection of skin and soft tissue infection pathogens: report from the SENTRY antimicrobial surveillance program (1999-2004).
Fritsche TR; Sader HS; Jones RN
Diagn Microbiol Infect Dis; 2007 May; 58(1):19-26. PubMed ID: 17383139
[TBL] [Abstract][Full Text] [Related]
10. Comparative in vitro activity of tigecycline and other antimicrobials against Gram-negative and Gram-positive organisms collected from the Asia-Pacific Rim as part of the Tigecycline Evaluation and Surveillance Trial (TEST).
Bouchillon SK; Iredell JR; Barkham T; Lee K; Dowzicky MJ
Int J Antimicrob Agents; 2009 Feb; 33(2):130-6. PubMed ID: 18995992
[TBL] [Abstract][Full Text] [Related]
11. Polyamine effects on antibiotic susceptibility in bacteria.
Kwon DH; Lu CD
Antimicrob Agents Chemother; 2007 Jun; 51(6):2070-7. PubMed ID: 17438056
[TBL] [Abstract][Full Text] [Related]
12. Synthesis of lipophilic dimeric C-7/C-7-linked ciprofloxacin and C-6/C-6-linked levofloxacin derivatives. Versatile in vitro biological evaluations of monomeric and dimeric fluoroquinolone derivatives as potential antitumor, antibacterial or antimycobacterial agents.
Azéma J; Guidetti B; Korolyov A; Kiss R; Roques C; Constant P; Daffé M; Malet-Martino M
Eur J Med Chem; 2011 Dec; 46(12):6025-38. PubMed ID: 22036229
[TBL] [Abstract][Full Text] [Related]
13. [Investigation of the effect of efflux pump inhibitors to MIC values of ciprofloxacin in clinical isolates of Pseudomonas aeruginosa, Escherichia coli, Acinetobacter baumannii and Staphylococcus aureus].
Cetinkaya E; Coban AY; Durupinar B
Mikrobiyol Bul; 2008 Oct; 42(4):553-61. PubMed ID: 19149076
[TBL] [Abstract][Full Text] [Related]
14. [Quinolone resistance in Gram negative rods in Iceland and association with antibiotic use].
Jónsdóttir K; Kristinsson KG
Laeknabladid; 2008 Apr; 94(4):279-85. PubMed ID: 18460726
[TBL] [Abstract][Full Text] [Related]
15. Activity of meropenem as serine carbapenemases evolve in US Medical Centers: monitoring report from the MYSTIC Program (2006).
Rhomberg PR; Deshpande LM; Kirby JT; Jones RN
Diagn Microbiol Infect Dis; 2007 Dec; 59(4):425-32. PubMed ID: 17662557
[TBL] [Abstract][Full Text] [Related]
16. In vitro activity of WQ-3810, a novel fluoroquinolone, against multidrug-resistant and fluoroquinolone-resistant pathogens.
Kazamori D; Aoi H; Sugimoto K; Ueshima T; Amano H; Itoh K; Kuramoto Y; Yazaki A
Int J Antimicrob Agents; 2014 Nov; 44(5):443-9. PubMed ID: 25239276
[TBL] [Abstract][Full Text] [Related]
17. Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004).
Biedenbach DJ; Bell JM; Sader HS; Fritsche TR; Jones RN; Turnidge JD
Int J Antimicrob Agents; 2007 Aug; 30(2):143-9. PubMed ID: 17531446
[TBL] [Abstract][Full Text] [Related]
18. Characterization of fluoroquinolone-resistant beta-hemolytic Streptococcus spp. isolated in North America and Europe including the first report of fluoroquinolone-resistant Streptococcus dysgalactiae subspecies equisimilis: report from the SENTRY Antimicrobial Surveillance Program (1997-2004).
Biedenbach DJ; Toleman MA; Walsh TR; Jones RN
Diagn Microbiol Infect Dis; 2006 Jun; 55(2):119-27. PubMed ID: 16530373
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, and evaluation of novel fluoroquinolone-aminoglycoside hybrid antibiotics.
Pokrovskaya V; Belakhov V; Hainrichson M; Yaron S; Baasov T
J Med Chem; 2009 Apr; 52(8):2243-54. PubMed ID: 19301822
[TBL] [Abstract][Full Text] [Related]
20. A longitudinal analysis of antimicrobial susceptibility in clinical institutions in Germany as part of the Tigecycline Evaluation and Surveillance Trial (2004-2007).
Seifert H; Dowzicky MJ
Chemotherapy; 2009; 55(4):241-52. PubMed ID: 19468222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
